In the present study, the interplay between expression of proteasome subunits and cisplatin resistance has been investigated by a CRISPR/Cas9 dropout screen in a pair of cell lines that resemble clinically relevant features of ovarian carcinoma (i.e., activation of survival pathways and TP53 mutation). This evidence concerns the gene TP53 and ovarian carcinoma.